Danaher (NYSE:DHR) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Danaher (NYSE:DHR) in a research report report published on Friday, Benzinga reports. Royal Bank of Canada currently has a $300.00 price objective on the conglomerate’s stock.

Several other research analysts have also issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a neutral rating in a research report on Wednesday, July 24th. Evercore ISI cut their target price on Danaher from $266.00 to $260.00 and set an outperform rating for the company in a research report on Tuesday, July 2nd. Bank of America upped their price target on Danaher from $270.00 to $275.00 and gave the company a neutral rating in a research report on Wednesday, July 24th. Barclays boosted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an equal weight rating in a research note on Wednesday, July 24th. Finally, Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the company an outperform rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has a consensus rating of Moderate Buy and a consensus price target of $278.94.

Danaher Trading Up 0.6 %

Danaher stock opened at $266.19 on Friday. Danaher has a 12 month low of $182.09 and a 12 month high of $281.70. The stock has a market cap of $197.16 billion, a price-to-earnings ratio of 45.12, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The business has a 50 day moving average price of $261.30 and a two-hundred day moving average price of $255.73. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business earned $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. As a group, equities analysts forecast that Danaher will post 7.59 EPS for the current year.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Norges Bank bought a new stake in shares of Danaher in the 4th quarter valued at about $1,752,382,000. Vanguard Group Inc. increased its stake in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP raised its holdings in Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Swedbank AB bought a new position in shares of Danaher during the first quarter worth $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after buying an additional 2,096,038 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.